2022
DOI: 10.1186/s12931-022-02119-1
|View full text |Cite
|
Sign up to set email alerts
|

CEBPD modulates the airway smooth muscle transcriptomic response to glucocorticoids

Abstract: Background CCAAT/Enhancer Binding Protein D (CEBPD), a pleiotropic glucocorticoid-responsive transcription factor, modulates inflammatory responses. Of relevance to asthma, expression of CEBPD in airway smooth muscle (ASM) increases with glucocorticoid exposure. We sought to characterize CEBPD-mediated transcriptomic responses to glucocorticoid exposure in ASM by measuring changes observed after knockdown of CEBPD and its impact on asthma-related ASM function. Met… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 41 publications
0
2
0
Order By: Relevance
“…1F and Supplemental Table 2). Conversely, target genes for GATA transcription factors and CCAAT enhancer binding protein delta (CEBPD), a positive transcriptional regulator of inflammatory responses mediated by interleukin-1 (IL-1) and IL-6 [40][41][42][43] , were enriched among transcripts upregulated in LDS VSMCs (Fig. 1G and Supplemental Table 2).…”
Section: Resultsmentioning
confidence: 99%
“…1F and Supplemental Table 2). Conversely, target genes for GATA transcription factors and CCAAT enhancer binding protein delta (CEBPD), a positive transcriptional regulator of inflammatory responses mediated by interleukin-1 (IL-1) and IL-6 [40][41][42][43] , were enriched among transcripts upregulated in LDS VSMCs (Fig. 1G and Supplemental Table 2).…”
Section: Resultsmentioning
confidence: 99%
“…The primary benefit of GWASs is their capability to carefully and objectively look into novel variants connected to a disease. GWASs, which have since 2007 found hundreds of genetic variants that may cause asthma, have enabled the creation of a systematic GWAS of disease vulnerability variations [ 31 ]. The very first GWAS on asthma that was carried out included 900 patients with asthma that started in infancy and 1,245 healthy controls with European ancestry.…”
Section: Reviewmentioning
confidence: 99%